Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab vs IVMP After Orbital Decompression in DON
NCT07594912Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of teprotumumab in dysthyroid optic neuropathy (DON), sponsored by Sun Yat-sen University. Primary endpoint: Best-Corrected Visual Acuity at 24 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
teprotumumab
03
Conditions
dysthyroid optic neuropathy (DON)
Beyond the preview
Go deeper on NCT07594912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594912.